Company Profile
Capricor Therapeutics Stock Price, News & Analysis
- Ticker:
- CAPR
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Capricor Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
29.60 USD (+0.89%)
Close
Last updated: June 23, 2026 at 00:00
1.71B USD
Market cap
Why the stock is moving
CAPR is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Capricor Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Capricor Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Capricor Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Capricor Therapeutics to Present at Upcoming Investor Conferences
Source: Capricor Therapeutics
- 02
Capricor Therapeutics Expands Commercial Leadership Team
Source: Capricor Therapeutics
- 03
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Capricor Therapeutics
- 04
Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
Source: Capricor Therapeutics
- 05
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Source: Capricor Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Capricor Therapeutics (CAPR)?
Capricor Therapeutics (CAPR) most recently closed at 29.60 USD, a +0.89% move versus the previous session.
What is the market cap of Capricor Therapeutics (CAPR)?
Capricor Therapeutics currently has a market capitalization of 1.71B USD on BioPharmSignal.
What does Capricor Therapeutics do?
Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is CAPR stock listed?
Capricor Therapeutics (CAPR) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Capricor Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Capricor?
Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Capricor Therapeutics targeting with Capricor?
Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.